Type 2 Diabetes Across the Continuum of Care: Current Approaches for Glycemic Control in the Inpatient and Outpatient Setting

Faculty

Needs Statement

Type 2 diabetes is a common, chronic, and expensive disease that affects nearly 20 million individuals in the United States. The increased prevalence of type 2 diabetes, which is largely attributed to the alarming increase in the US obesity rate, results in a substantial clinical burden, including an increased risk of cardiovascular death. Costs associated with diabetes and its related comorbidities total more than $170 billion annually. Morbidity and mortality in patients with type 2 diabetes is often linked to inadequate glycemic control. Recent studies have demonstrated that despite the availability of appropriate therapy and an increasing antidiabetic treatment armamentarium, glycemic control in patients with type 2 diabetes deteriorates over time and more than 60% of individuals with this condition are insufficiently managed. Hospital pharmacists and managed markets professionals may benefit from education on current and emerging evidence-based approaches to ensure proper glycemic management to optimize patient outcomes and ensure efficient healthcare resource use.

Target Audience

This activity is designed for hospital pharmacists and managed markets professionals.

Objectives

After completing this activity, participants should be able to:
1. Describe the prevalence and burden of type 2 diabetes, including frequent comorbidities, such as obesity and cardiovascular disease (CVD);
2. Explain the importance of tight glucose control in type 2 diabetes management and its correlation with obesity and CVD;
3. Outline the benefits and limitations of current and emerging medications and combinations for type 2 diabetes management;
4. Implement evidence-based approaches to type 2 diabetes management to optimize patient outcomes across the continuum of care.

Accreditation

Medicine
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Pharmacy
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 425-999-08-021-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Princeton CME may contact John Savage, Director, Medical Education, North American Center for Continuing Medical Education (NACCME)-Princeton CME, in writing. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME-Princeton CME, may be made for a second level of review.

John Savage
NACCME-Princeton CME
300 Rike Drive, Suite A
Millstone Township, NJ 08535
E-mail: jsavage@naccme.com

Faculty Disclosure

According to the disclosure policy of the University of Kentucky College of Medicine and NACCME-Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Kentucky College of Medicine and NACCME-Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Independent Clinical Reviewer
Derek LeRoith, MD, PhD
Chief, Division of Endocrinology, Diabetes, and Bone Diseases
Mount Sinai School of Medicine

Dr. Ahmann serves on the speakers bureau for Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Merck & Co, Inc, sanofi-aventis U.S.; he has received research support from Amylin Pharmaceuticals, Inc, Eli Lilly and Company, Medtronic; and he serves as a consultant to Novo Nordisk.

Dr. Gleeson serves on the speakers bureau for Amylin Pharmaceuticals, Inc, Diiachi Sankyo, Inc, Merck & Co, Inc, Novartis and Takeda Pharmaceuticals North America, Inc.

Dr. Haines serves as a consultant to Amylin Pharmaceuticals, Inc and has directly purchased stock from Merck & Co, Inc.

Dr. LeRoith serves on the speakers bureau for Pfizer, Inc, sanofi-aventis U.S.; and serves as a consultant to Merck & Co, Inc, Novo Nordisk and Takeda Pharmaceuticals North America, Inc.

All members of the planning committee report they have no relevant financial relationships with commercial interests of healthcare products or services related to this activity.

To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Estimated time to complete: 1 hour

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

 

Privacy Policy

NACCME-Princeton CME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME-Princeton CME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME-Princeton CME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Activity Sponsorship

Supported by an unrestricted educational grant from, Amylin Pharmaceuticals, Inc, and Eli Lilly and Company.